Skip to main content

Advertisement

SpringerLink
Log in

Cost-effectiveness of posaconazole tablets versus fluconazole as prophylaxis for invasive fungal diseases in patients with graft-versus-host disease after allogeneic hematopoietic stem cell transplantation

  • Original Paper
  • Published:
The European Journal of Health Economics Aims and scope Submit manuscript

Abstract

Background

The cost-effectiveness of posaconazole oral suspension versus fluconazole capsules for the prophylaxis of invasive fungal diseases (IFDs) in immunosuppressed allogeneic hematopoietic stem cell transplantation (HSCT) recipients has already been proven. Now, a new solid oral tablet formulation for posaconazole has been developed with improved bioavailability, allowing a reduced daily dosage that can be taken independently of food intake. However, the efficacy of this new formulation should be evaluated since it is associated with a higher cost than the posaconazole oral suspension.

Objectives

To evaluate the cost-effectiveness of solid oral tablets of posaconazole versus fluconazole capsules for the prophylaxis of IFDs in allogeneic HSCT recipients with graft-versus-host disease (GVHD) in Spain.

Methodology

A mathematical model comparing the efficacy and costs of posaconazole versus fluconazole was adapted to the Spanish National Healthcare System. Clinical data were obtained from the pivotal clinical trial of posaconazole oral suspension for allogeneic HSCT recipients, while pharmacological costs and use of resources were obtained from national sources. Deterministic and probabilistic sensitivity analyses (PSA), as well as two alternative scenarios, were run to evaluate the robustness of the results under varying input values.

Results

Posaconazole tablets reduced the number of IFD events and enhanced overall survival, while maintaining a controlled budget. When compared to fluconazole, it was found to be a cost-effective alternative, with an incremental cost-effectiveness ratio of €13,193/life years gained. The PSA showed that posaconazole remained cost-effective in 74.6% of the cases, while alternatives scenarios yielded similar results as the base case.

Conclusions

Posaconazole tablets are a cost-effective alternative to fluconazole and may show better results than the oral suspension formulation.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

References

  1. Busca, A., Pagano, L.: Antifungal therapy in hematopoietic stem cell transplant recipients. Mediterr. J. Hematol. Infect. Dis. 8(1), 1–12 (2016)

    Google Scholar 

  2. Binder, U., Lass-Flörl, C.: Epidemiology of invasive fungal infections in the Mediterranean area. Mediterr. J. Hematol. Infect. Dis. 3(1), 1–9 (2011)

    Article  Google Scholar 

  3. Vallejo, J.C., Ruiz-camps, I.: Infección fúngica invasora en los pacientes hematológicos. Enfermedades Infecc. Microbiol. Clín. 30(9), 572–579 (2012)

    Article  Google Scholar 

  4. von Eiff, M., Roos, N., Schulten, R., Hesse, M., Zühlsdorf, M., van de Loo, J.: Pulmonary aspergillosis: early diagnosis improves survival. Respiration 62(6), 341–347 (1995)

    Article  Google Scholar 

  5. Hope, W.W., Walsh, T.J.D.D.: Laboratory diagnosis of invasive aspergillosis. Lancet Infect. Dis. 5(10), 609–622 (2005)

    Article  CAS  PubMed  Google Scholar 

  6. Ullmann, A.J., Schmidt-Hieber, M., Bertz, H., Heinz, W.J., Kiehl, M., Krüger, W., et al.: Infectious diseases in allogeneic haematopoietic stem cell transplantation: prevention and prophylaxis strategy guidelines 2016. Ann. Hematol. 95(9), 1435–1455 (2016)

    Article  PubMed  PubMed Central  Google Scholar 

  7. Goodman, J., Winston, D., Greenfield, R., Chandrasekar, P., Fox, B., Kaizer, H., et al.: A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N. Engl. J. Med. 326(13), 845–851 (1992)

    Article  CAS  PubMed  Google Scholar 

  8. Slavin, M., Osborne, B., Adams, R., Levenstein, M., Schoch, H., Feldman, A., et al.: Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation—a prospective, randomized, double-blind study. J. Infect. Dis. 171(6), 1545–1552 (1995)

    Article  CAS  PubMed  Google Scholar 

  9. Marr, K., Seidel, K., Slavin, M., Bowden, R., Schoch, H., Flowers, M., et al.: Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis-related death in allogeneic marrow transplant recipients: long-term follow-up of a randomized, placebo-controlled trial. Blood 96(6), 2055–2061 (2000)

    CAS  PubMed  Google Scholar 

  10. CDC, Infectious Disease Society of America and the AS of B and MT: Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. Recommendations of CDC, the Infectious Disease Society of America, and the American Society of Blood and Marrow Transplantation. Cytotherapy 3(1), 41–54 (2001)

    Article  Google Scholar 

  11. Ullmann, A.J., Lipton, J.H., Vesole, D.H., Chandrasekar, P., Langston, A., Tarantolo, S.R., et al.: Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N. Engl. J. Med. 365(4), 335–347 (2007)

    Article  Google Scholar 

  12. O’Sullivan, A.K., Weinstein, M.C., Pandya, A., Thompson, D., Langston, A.A., Perfect, J.R., et al.: Cost-effectiveness of posaconazole versus fluconazole for prevention of invasive fungal infections in US patients with graft-versus-host disease. Am. J. Health Pharm. 69(2), 149–156 (2012)

    Article  Google Scholar 

  13. Jansen, J.P., O’Sullivan, A.K., Lugtenburg, E., Span, L.F.R., Janssen, J.J.W.M., Stam, W.B.: Economic evaluation of posaconazole versus fluconazole prophylaxis in patients with graft-versus-host disease (GVHD) in the Netherlands. Ann. Hematol. 89(9), 919–926 (2010)

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Cámara, R., Jarque, I., Sanz, M.A., Grau, S., Casado, M.A., Sabater, F.J., et al.: Economic evaluation of posaconazole vs fluconazole in the prevention of invasive fungal infections in patients with GVHD following haematopoietic SCT. Bone Marrow Transplant. 45(5), 925–932 (2010)

    Article  PubMed  Google Scholar 

  15. Inc. M & C.: Noxafil (posaconazole) [prescribing information]. Merk Co., Inc., Whitehouse Station, NJ (2014)

  16. Courtney, R., Wexler, D., Radwanski, E., Lim, J., Laughlin, M.: Effect of food on the relative bioavailability of two oral formulations of posaconazole in healthy adults. Br. J. Clin. Pharmacol. 57(2), 218–222 (2003)

    Article  Google Scholar 

  17. Krishna, G., Ma, L., Martinho, M., Preston, R.A., O’mara, E.: A new solid oral tablet formulation of posaconazole: a randomized clinical trial to investigate rising single- and multiple-dose pharmacokinetics and safety in healthy volunteers. J. Antimicrob. Chemother. 67(11), 2725–2730 (2012)

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Sansone-parsons, A., Krishna, G., Calzetta, A., Wexler, D., Kantesaria, B., Rosenberg, M.A., et al.: Effect of a nutritional supplement on posaconazole pharmacokinetics following oral administration to healthy volunteers. Antimicrob. Agents Chemother. 50(5), 1881–1883 (2006)

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Vehreschild, M.J.G.T., Meißner, A.M.K., Cornely, O.A., Maschmeyer, G., Neumann, S., von Lilienfeld-Toal, M., et al.: Clinically defined chemotherapy-associated bowel syndrome predicts severe complications and death in cancer patients. Haematologica 96(12), 1855–1860 (2011)

    Article  PubMed  PubMed Central  Google Scholar 

  20. Cornely, O.A., Duarte, R.F., Haider, S., Chandrasekar, P., Helfgott, D., Jiménez, J.L., et al.: Phase 3 pharmacokinetics and safety study of a posaconazole tablet formulation in patients at risk for invasive fungal disease. J. Antimicrob. Chemother. 71(3), 718–726 (2016)

    Article  CAS  PubMed  Google Scholar 

  21. Durani, U., Tosh, P.K., Barreto, J.N., Estes, L.L., Jannetto, P.J., Tande, A.J.: Retrospective comparison of posaconazole levels in patients taking the delayed-release tablet versus the oral suspension. Antimicrob. Agents Chemother. 59(8), 4914–4918 (2015)

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Wingard, J.R., Majhail, N.S., Brazauskas, R., Wang, Z., Sobocinski, K.A., Jacobsohn, D., et al.: Long-term survival and late deaths after allogeneic hematopoietic cell transplantation. J. Clin. Oncol. 29(16), 2230–2239 (2011)

    Article  PubMed  PubMed Central  Google Scholar 

  23. INE. Instituto Nacional de Estadística. [Life expectancy at birth according to gender] (2014) [cited 2016 Jun 1]. www.ine.es

  24. Mitchell M. Engauge Digitizer (2015)

  25. Guyot, P., Ades, A., Ouwens, M.J., Welton, N.J.: Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves. BMC Med. Res. Methodol. 12, 9 (2012)

    Article  PubMed  PubMed Central  Google Scholar 

  26. R-CoreTeam. R Foundation for Statistical Computing, Vienna A. R 3.2.2. 2015

  27. Consulting O. eSalud—Información económica del sector sanitario. [cited 2016 Apr 1]. https://www.oblikue.com/bddcostes/

  28. Oblikue. Base de datos de costes. [cited 2016 Jun 1]. http://www.oblikue.com/bddcostes/index.asp

  29. Grau Cerrato, S., Mateu de Antonio, J., Soto Álvarez, J., Muñoz Jareño, M.A., Salas Sánchez, E., Marín, Casino M.: Evaluación económica del uso de voriconazol versus anfotericina B en el tratamiento de la aspergilosis invasiva. Farm. Hosp. 29(1), 5–10 (2005)

    Article  CAS  PubMed  Google Scholar 

  30. CCEMG-EPPI-Centre. Cost Converter v.1.5 . [cited 2016 Apr 1]. http://eppi.ioe.ac.uk/costconversion/default.aspx

  31. López-Bastida, J., Oliva, J., Antoñanzas, F., García-Altés, A., Gisbert, R., Mar, J., et al.: Spanish recommendations on economic evaluation of health technologies. Eur. J. Health Econ. 11(5), 513–520 (2010)

    Article  PubMed  Google Scholar 

  32. Palmer, J., Chai, X., Pidala, J., Inamoto, Y., Martin, P.J., Storer, B., et al.: Predictors of survival, non-relapse mortality and failure-free survival in patients treated for chronic graft-versus-host disease. Blood 127(1), 160 (2015)

    Article  PubMed  Google Scholar 

  33. Levine, J.E., Logan, B., Wu, J., Alousi, A.M., Ho, V., Bolaños-Meade, J., et al.: Graft-versus-host disease treatment: predictors of survival. Biol. Blood Marrow Transplant. 16(12), 1693–1699 (2011)

    Article  Google Scholar 

  34. Sacristán, J.A., Oliva, J., Del, Llano J., Prieto, L.: ¿Qué es una tecnología sanitaria eficiente en España? Gac. Sanit. 16(4), 334–343 (2002)

    Article  PubMed  Google Scholar 

  35. Sun, Y., Xu, L., Liu, D., Zhang, X., Han, W., Wang, Y., et al.: Incidence of invasive fungal disease after unmanipulated haploidentical stem cell transplantation was significantly higher than that after HLA-matched sibling transplantation. Clin. Microbiol. Infect. 19(11), 1029–1034 (2013)

    Article  CAS  PubMed  Google Scholar 

  36. Papadopoulos, G., Hunt, S., Prasad, M.: Adapting a global cost-effectiveness model to local country requirements: posaconazole case study. J. Med. Econ. 16(3), 374–380 (2013)

    Article  PubMed  Google Scholar 

  37. Harrison, N., Mitterbauer, M., Tobudic, S., Kalhs, P., Rabitsch, W., Greinix, H., et al.: Incidence and characteristics of invasive fungal diseases in allogeneic hematopoietic stem cell transplant recipients: a retrospective cohort study. BMC Infect. Dis. 15, 584 (2015)

    Article  PubMed  PubMed Central  Google Scholar 

  38. Girmenia, C., Raiola, A.M., Piciocchi, A., Algarotti, A., Stanzani, M., Cudillo, L., et al.: Incidence and outcome of invasive fungal diseases after allogeneic stem cell transplantation: a prospective study of the Gruppo Italiano Trapianto Midollo Osseo (GITMO). Biol. Blood Marrow Transplant. 20(6), 872–880 (2014)

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

The study was funded by MSD Sharp & Dohme.

Author information

Authors and Affiliations

  1. Pharmacy Department, Del Mar Hospital, Barcelona, Spain

    Santiago Grau

  2. La Princesa Hospital, Calle de Diego de León, 62, 28006, Madrid, Spain

    Rafael Cámara

  3. Virgen de las Nieves University Hospital, Granada, Spain

    Manuel Jurado

  4. La Fe University Hospital, Valencia, Spain

    Jaime Sanz

  5. Merck Sharp & Dohme Corp., Madrid, Spain

    Belén Aragón

  6. Outcomes10, Castellon, Spain

    Irmina Gozalbo

Authors
  1. Santiago Grau
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Rafael Cámara
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Manuel Jurado
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jaime Sanz
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Belén Aragón
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Irmina Gozalbo
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Rafael Cámara.

Ethics declarations

Conflict of interests

The authors RC, MJ, JS, and SG declare they have no conflict of interest. BA works at MSD Sharp & Dohme. IG works for an independent research institution and received payment for her contribution to the development of the project as well as to the drafting of this manuscript.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Grau, S., Cámara, R., Jurado, M. et al. Cost-effectiveness of posaconazole tablets versus fluconazole as prophylaxis for invasive fungal diseases in patients with graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Eur J Health Econ 19, 627–636 (2018). https://doi.org/10.1007/s10198-017-0907-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10198-017-0907-5

Keywords

JEL Classification

Search

Navigation